Analyzing Ekso Bionics (NASDAQ:EKSO) and iRadimed (NASDAQ:IRMD)

Ekso Bionics (NASDAQ:EKSO) and iRadimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility and Risk

Ekso Bionics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

6.4% of Ekso Bionics shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 6.0% of Ekso Bionics shares are owned by company insiders. Comparatively, 36.8% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Ekso Bionics and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ekso Bionics	-91.37%	-110.52%	-50.71%
iRadimed	26.82%	23.83%	20.83%

Analyst Recommendations

This is a summary of current ratings for Ekso Bionics and iRadimed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ekso Bionics	1	1	0	0	1.50
iRadimed	0	1	3	1	3.00

Ekso Bionics currently has a consensus target price of $6.00, suggesting a potential downside of 44.50%. iRadimed has a consensus target price of $120.00, suggesting a potential upside of 28.05%. Given iRadimed’s stronger consensus rating and higher probable upside, analysts plainly believe iRadimed is more favorable than Ekso Bionics.

Valuation & Earnings

This table compares Ekso Bionics and iRadimed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ekso Bionics	$12.80 million	3.01	-$11.69 million	($5.14)	-2.10
iRadimed	$83.81 million	14.29	$22.48 million	$1.75	53.55

iRadimed has higher revenue and earnings than Ekso Bionics. Ekso Bionics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Summary

iRadimed beats Ekso Bionics on 15 of the 15 factors compared between the two stocks.

About Ekso Bionics

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.